Search results for "aRR"

showing 10 items of 10185 documents

Fungal Deoxynivalenol-Induced Enterocyte Distress Is Attenuated by Adulterated Adlay: In Vitro Evidences for Mucoactive Counteraction

2018

Adlay is a cereal crop that has long been used as traditional herbal medicine and as a highly nourishing food. However, deoxynivalenol (DON), the most prevalent trichothecene mycotoxin worldwide, frequently spoils grains, including adlay, via fungal infection. On the basis of an assumption that the actions of DON in the gut could be modified by adlay consumption, we simulated the impacts of co-exposure in enterocytes and investigated the effectiveness of treatment with adlay for reducing the risk of DON-induced inflammation and epithelia barrier injury. In particular, adlay suppressed DON-induced pro-inflammatory signals such as mitogen-activated kinase transduction and the epidermal growth…

0301 basic medicinelcsh:Immunologic diseases. AllergyEnterocytewoundImmunologyTrichothecenedeoxynivalenolInflammationPharmacologyBiologyadlay03 medical and health sciences0302 clinical medicineEpidermal growth factormedicineImmunology and AllergyProtein kinase Cgut barrierKinasefood and beveragesIn vitroCytosol030104 developmental biologymedicine.anatomical_structureinflammation030220 oncology & carcinogenesismedicine.symptomlcsh:RC581-607Frontiers in Immunology
researchProduct

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery

2018

Nanocarriers (NC) are very promising tools for cancer immunotherapy. Whereas conventional vaccines are based on the administration of an antigen and an adjuvant in an independent fashion, nanovaccines can facilitate cell-specific co-delivery of antigen and adjuvant. Furthermore, nanovaccines can be decorated on their surface with molecules that facilitate target-specific antigen delivery to certain antigen-presenting cell types or tumor cells. However, the target cell-specific uptake of nanovaccines is highly dependent on the modifications of the nanocarrier itself. One of these is the formation of a protein corona around NC after in vivo administration, which may potently affect cell-speci…

0301 basic medicinelcsh:Immunologic diseases. AllergyMini Reviewmedicine.medical_treatmentImmunologyCellcell-specific targetingProtein Corona02 engineering and technology03 medical and health sciencesprotein coronaAntigenCancer immunotherapyIn vivoNeoplasmsmedicineHumansImmunology and AllergyReceptors ImmunologicnanocarriersChemistryImmunotherapy021001 nanoscience & nanotechnologyBody FluidsTreatment Outcome030104 developmental biologymedicine.anatomical_structureCancer researchNanoparticlesimmunotherapyNanocarriers0210 nano-technologylcsh:RC581-607Adjuvantcancer vaccinesProtein BindingFrontiers in Immunology
researchProduct

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression

2018

Vγ9Vδ2 T cells are non-conventional T cells with a natural inclination to recognize and kill cancer cells. Malignant B cells, including myeloma cells, are privileged targets of Vγ9Vδ2 T cells in vitro. However, this inclination is often lost in vivo due to multiple mechanisms mediated by tumor cells and local microenvironment. Multiple myeloma (MM) is a paradigm disease in which antitumor immunity is selectively impaired at the tumor site. By interrogating the immune reactivity of bone marrow (BM) Vγ9Vδ2 T cells to phosphoantigens, we have revealed a very early and long-lasting impairment of Vγ9Vδ2 T-cell immune functions which is already detectable in monoclonal gammopathy of undetermined …

0301 basic medicinelcsh:Immunologic diseases. AllergyStromal cellbone marrowMini ReviewImmunologyVγ9Vδ2 T cells immune checkpoints multiple myeloma immune suppression bone marrow03 medical and health sciences0302 clinical medicineImmune systemAutologous stem-cell transplantationmedicineImmunology and AllergyMultiple myelomabusiness.industryimmune checkpointsmedicine.diseaseVγ9Vδ2 T cellsIn vitromultiple myeloma030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer cellCancer researchBone marrowimmune suppressionbusinesslcsh:RC581-607Monoclonal gammopathy of undetermined significanceFrontiers in Immunology
researchProduct

The Ontogeny of Monocyte Subsets

2019

Classical and non-classical monocytes, and the macrophages and monocyte-derived dendritic cells they produce, play key roles in host defense against pathogens, immune regulation, tissue repair and many other processes throughout the body. Recent studies have revealed previously unappreciated heterogeneity among monocytes that may explain this functional diversity, but our understanding of mechanisms controlling the functional programming of distinct monocyte subsets remains incomplete. Resolving monocyte heterogeneity and understanding how their functional identity is determined holds great promise for therapeutic immune modulation. In this review, we examine how monocyte origins and develo…

0301 basic medicinelcsh:Immunologic diseases. Allergybone marrowOntogenyMini ReviewImmunologyInflammationDiseaseBiologyMonocytes03 medical and health sciences0302 clinical medicinemonocyte subsetsmedicineImmunology and AllergyAnimalsHumansEpigeneticsProgenitor cellInflammationMonocytemonopoiesisMacrophagesDendritic CellsPhenotype3. Good health030104 developmental biologymedicine.anatomical_structureGene Ontologymonocyte progenitorsmedicine.symptomlcsh:RC581-607Neurosciencemonocyte ontogenyHomeostasis030215 immunologyFrontiers in Immunology
researchProduct

Localized Interleukin-12 for Cancer Immunotherapy

2020

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Early clinical trials in the mid-1990's showed that systemic delivery of IL-12 incurred dose-limiting toxicities. Nevertheless, IL-12's pleiotropic activity, i.e., its ability to engage multiple effector mechanisms and reverse tumor-induced immunosuppression, continues to entice cancer researchers. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentDrug CompoundingImmunologyGenetic Vectorsinterleukin-12 (IL-12)Antineoplastic AgentsReviewBioinformatics03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsintratumoral administrationTumor MicroenvironmentImmunology and AllergyMedicineAnimalsHumansTumor microenvironmentDrug Carrierscancer immunotherapyAntitumor immunitybusiness.industryGene Transfer TechniquesCancerImmunotherapyGenetic Therapymedicine.diseaseInterleukin-12Clinical trialcytokine delivery system030104 developmental biologyTreatment OutcomeInterleukin 12Cancer vaccineImmunotherapybusinesslcsh:RC581-607cancer vaccinelocalized delivery030215 immunologyFrontiers in Immunology
researchProduct

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

2020

Autologous T cells engineered to express a chimeric antigen receptor (CAR) against the CD19 antigen are in the frontline of contemporary hemato-oncology therapies, leading to high remission rates in B-cell malignancies. Although effective, major obstacles involve the complex and costly individualized manufacturing process, and CD19 target antigen loss or modulation leading to resistant and relapse following CAR therapy. A potential solution for these limitations is the use of donor-derived γδT cells as a CAR backbone. γδT cells lack allogenecity and are safely used in haploidentical transplants. Moreover, γδT cells are known to mediate natural anti-tumor responses. Here, we describe a 14-da…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentImmunologyCell Culture TechniquesPriming (immunology)Mice SCIDImmunotherapy AdoptiveCD1903 medical and health sciencesMice0302 clinical medicineAntigenMice Inbred NODTransduction GeneticmedicineAnimalsHumansImmunology and Allergyimmuno oncologyB cell malignanciesOriginal ResearchLeukemiaReceptors Chimeric Antigenbiologychimeric antigen receptorChemistrygamma-delta T cellsReceptors Antigen T-Cell gamma-deltamedicine.diseaseXenograft Model Antitumor AssaysChimeric antigen receptorLeukemia030104 developmental biologyCytokinemedicine.anatomical_structureCell cultureCancer researchbiology.proteinBone marrowlcsh:RC581-607Genetic Engineering030215 immunologyFrontiers in Immunology
researchProduct

Dynamics of a Protein Interaction Network Associated to the Aggregation of polyQ-Expanded Ataxin-1

2020

Background: Several experimental models of polyglutamine (polyQ) diseases have been previously developed that are useful for studying disease progression in the primarily affected central nervous system. However, there is a missing link between cellular and animal models that would indicate the molecular defects occurring in neurons and are responsible for the disease phenotype in vivo. Methods: Here, we used a computational approach to identify dysregulated pathways shared by an in vitro and an in vivo model of ATXN1(Q82) protein aggregation, the mutant protein that causes the neurodegenerative polyQ disease spinocerebellar ataxia type-1 (SCA1). Results: A set of common dysregulated pathwa…

0301 basic medicinelcsh:QH426-470Ataxin 1Mice TransgenicNerve Tissue ProteinsProtein aggregationBlood–brain barrierblood-brain-barrierArticledrugspolyQ03 medical and health sciences0302 clinical medicineataxin-1Interaction networkIn vivoMutant proteinCerebellumGeneticsmedicineAnimalsGene Regulatory NetworksProtein Interaction MapsGenetics (clinical)NeuronsbiologypathwayGene Expression Profilingmedicine.diseaselcsh:Genetics030104 developmental biologymedicine.anatomical_structureGene Expression Regulationnetworkbiology.proteinSpinocerebellar ataxiaPeptidesNeuroscience030217 neurology & neurosurgeryFunction (biology)Genes
researchProduct

Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology

2020

Bone remodeling is uncoupled in the multiple myeloma (MM) bone marrow niche, resulting in enhanced osteoclastogenesis responsible of MM-related bone disease (MMBD). Several studies have disclosed the mechanisms underlying increased osteoclast formation and activity triggered by the various cellular components of the MM bone marrow microenvironment, leading to the identification of novel targets for therapeutic intervention. In this regard, recent attention has been given to non-coding RNA (ncRNA) molecules, that finely tune gene expression programs involved in bone homeostasis both in physiological and pathological settings. In this review, we will analyze major signaling pathways involved …

0301 basic medicinelcsh:QH426-470Bone diseasenon-coding RNAReviewBiologyBiochemistryBone remodeling03 medical and health sciences0302 clinical medicineOsteoclastmicroRNAGeneticsmedicinetumor microenvironmentMolecular BiologyMultiple myelomamiRNAlong non-coding RNAmedicine.diseaseNon-coding RNALong non-coding RNAmultiple myelomalcsh:Genetics030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchbone diseaseBone marrowNon-Coding RNA
researchProduct

MARTX Toxin in the Zoonotic Serovar of Vibrio vulnificus Triggers an Early Cytokine Storm in Mice

2017

Vibrio vulnificus biotype 2-serovar E is a zoonotic clonal complex that can cause death by sepsis in humans and fish. Unlike other biotypes, Bt2 produces a unique type of MARTXVv (Multifunctional-Autoprocessive-Repeats-in-Toxin; RtxA13), which is encoded by a gene duplicated in the pVvBt2 plasmid and chromosome II. In this work, we analyzed the activity of this toxin and its role in human sepsis by performing in vitro, ex vivo, and in vivo assays. First, we demonstrated that the ACD domain, present exclusively in this toxin variant, effectively has an actin-cross-linking activity. Second, we determined that the whole toxin caused death of human endotheliocytes and monocytes by lysis and apo…

0301 basic medicinelcsh:QR1-502MicrobiologiaVibrio vulnificusmedicine.disease_causeMonocyteslcsh:MicrobiologysepsisVibrio vulnificusCells CulturedOriginal ResearchMice Inbred BALB CCell DeathVirulencebiologyqPCR arrayInfectious DiseasesHost-Pathogen InteractionsBacteris patògensCytokinesV. vulnificusFemaleMicrobiology (medical)Virulence FactorsBacterial ToxinsImmunologyVirulenceSerogroupMicrobiologyMicrobiology03 medical and health sciencesImmune systemMARTXIn vivomedicineAnimalsHumansVibrioToxinEndothelial Cellsbiology.organism_classificationmedicine.diseaseVirologyVibrioinfectionDisease Models Animal030104 developmental biologyInfecciógene expressionCytokine stormEx vivoFrontiers in Cellular and Infection Microbiology
researchProduct

Long Non-coding Antisense RNA TNRC6C-AS1 Is Activated in Papillary Thyroid Cancer and Promotes Cancer Progression by Suppressing TNRC6C Expression

2018

Context: Evidences have shown the important role of long non-coding antisense RNAs in regulating its cognate sense gene in cancer biology. Objective: Investigate the regulatory role of a long non-coding antisense RNA TNRC6C-AS1 on its sense partner TNRC6C, and their effects on the aggressiveness and iodine-uptake ability of papillary thyroid cancer (PTC). Design: TNRC6C-AS1 was identified as the target long non-coding RNA in PTC by using microarray analysis and computational analysis. In vitro gain/loss-of-function experiments were performed to investigate the effects of TNRC6C-AS1 and TNRC6C on proliferation, apoptosis, migration, invasion and iodine-uptake ability of TPC1 cells. Expressio…

0301 basic medicinelong non-coding antisense RNAendocrine system diseasesEndocrinology Diabetes and MetabolismTNRC6C-AS1lcsh:Diseases of the endocrine glands. Clinical endocrinologyPapillary thyroid cancer03 medical and health sciencesEndocrinology0302 clinical medicineDownregulation and upregulationSense (molecular biology)medicinepapillary thyroid cancerTNRC6COriginal Researchiodine accumulationGene knockdownMessenger RNAlcsh:RC648-665ChemistryMicroarray analysis techniquesRNAmedicine.diseaseAntisense RNA030104 developmental biology030220 oncology & carcinogenesisCancer researchFrontiers in Endocrinology
researchProduct